# XAIR earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/XAIR) · [Earnings tab](https://www.lopjlb.com/stock/XAIR?tab=earnings) Updated: 2026-08-13T07:25:59 Quarters analyzed: 8 ## Cross-quarter narrative Across six earnings calls, Beyond Air moved from a cash‑preserving, loss‑making posture in FY24 to a revenue‑growing, near‑profit operation by mid‑2026. Revenue accelerated from $1.2 M FY24 to $7.7 M in Q4 2026, while gross profit turned positive in early 2026 after successive cost cuts and a 40 %‑plus reduction in operating expenses. Guidance evolved from a lowered FY25 target to a maintained FY26 range of $12‑16 M, then briefly narrowed to $8‑10 M before re‑affirming the broader range, reflecting growing confidence in commercial execution. The company secured multiple financing rounds (equity, debt, royalty) that extended runway into 2027 despite ongoing liquidity warnings. Clinical and regulatory milestones progressed unevenly: CE Mark approval was delivered in 2025, but the cardiac‑surgery PMA supplement and Gen 2 FDA clearance remain at risk. International expansion accelerated, with distribution in 35‑40 countries and new GPO agreements covering thousands of hospitals. Competitive pressure from Mallinckrodt surfaced once, while recurring regulatory and market‑adoption risks continue to dominate the risk narrative. ## Latest CallCard · Q4 Beyond Air posted 107% revenue growth to $7.7M, 90% renewal rate and a swing to profitability, while betting on FDA approval of Gen 2 in H2 2026 and guiding calendar‑2026 revenue to $8M. **Guidance:** maintained — Guidance assumes no Gen 2 revenue in 2026 and FDA approval/commercial launch of Gen 2 in 2027. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3 Management highlighted strong revenue growth, high renewal rates, progress on Gen 2 FDA review and new GPO agreement, indicating optimism. ### Demand visibility Strong demand evidenced by 107% YoY revenue growth and 90% renewal rate. Growth driven by existing customer retention and new hospital adoption, with customers awaiting Gen 2 to meet broader INO needs. ### Margins / costs Margins improved through cost cuts and revenue scaling. R&D expenses fell 39% to $10.2M, SG&A down 27% to $19.1M, gross profit turned positive and net cash burn fell 56%. ### Capital allocation Capital directed toward LungFit PH commercialization and Gen 2 development with disciplined cost reductions. Resources allocated to commercial activities, FDA submission, GPO agreements; reverse split approved to regain Nasdaq compliance. ### Milestones - **LungFit PH revenue growth** [on_track]: Revenue up 107% YoY with ~90% renewal rate. - **Third major GPO agreement** [delivered]: Secured national purchasing agreement expanding U.S. market access. - **Regulatory clearance in 45+ countries** [delivered]: Achieved clearance in over 45 international markets. - **PMA supplement submission (June 2025)** [on_track]: Submitted supplement; FDA review ongoing, expecting H2 2026 approval. - **Gen 2 launch preparation** [at_risk]: Preparing for commercial launch by end‑2026 pending FDA approval. - **One‑for‑20 reverse split** [delivered]: Approved to meet Nasdaq bid‑price requirement by July 31 2026. - **Transition to calendar year‑end** [delivered]: Shifted fiscal year to calendar year, enabling FY2026 guidance. - **First‑time calendar‑2026 guidance** [delivered]: Provided $8M revenue guidance for calendar 2026. ### Fears / risks - **Regulatory risk**: FDA approval of Gen 2 is uncertain and could affect launch timing. - **Market adoption risk**: Revenue growth depends on GPO agreements and customer uptake of Gen 2. - **Liquidity risk**: Company reports $17.3M cash and $21.6M debt with a net loss of $33.2M, indicating cash pressure. - **Nasdaq compliance risk**: Must regain minimum bid price by July 31 2026; reverse split is a mitigation. - **Execution risk**: Scaling manufacturing and delivering Gen 2 features on schedule may be challenging. - **Competitive risk**: Existing nitric oxide devices could limit Gen 2 market share despite claimed advantages. ### Key quotes > “LungFit PH represents a significant commercial opportunity to establish Beyond Air as a leader in the nitric oxide market.” > “We submitted our PMA supplement to the FDA in June 2025 and continue to work through the review process at the expected pace.” > “With the second-generation supplement, we're completely on track. We've done all types of testing around our software, ventilator testing, cybersecurity, EMC testing, bootloader testing, altitude testing — all as asked by the FDA as part” — Robert Goodman > “The most recent GPO that we signed on April 1st is up and running, and we're already doing evaluations.” — Robert Goodman ## Quarter one-liners - **2026 Q4:** Beyond Air posted 107% revenue growth to $7.7M, 90% renewal rate and a swing to profitability, while betting on FDA approval of Gen 2 in H2 2026 and guiding calendar‑2026 revenue to $8M. - **2026 Q3:** Beyond Air reports 105% YoY revenue growth to $2.2M, positive gross profit, 36% OpEx reduction, $17.8M cash plus $4.5M financing extending runway into 2027; Gen II FDA decision expected end of 2026, NeuroNOS sold to XTL for 19.9% stake + milestones, commercial progress with VA sale and 40-country di - **2026 Q2:** Beyond Air reports 128% YoY revenue growth to $1.8M in FQ2'26, updates FY26 guidance to $8-10M, secures $12M debt + $20M equity line, targets Gen II launch late 2026, expands to 35 countries, introduces capital purchase model, transitions CCO. - **2026 Q1:** Beyond Air reports 157% YoY revenue growth to $1.8M in FQ1'26, reaffirms $12-16M FY26 guidance, highlights Premier GPO access and international expansion, cuts cash burn 60% to $4.7M. - **2025 Q4:** Beyond Air reported 220% revenue growth to $3.7M, set FY2026 revenue guidance of $12‑$16M, announced FDA PMA supplement for LungFit PH2, expanded international distribution, cut operating costs, but faces regulatory timing and cash runway uncertainties. - **2025 Q3:** Beyond Air reports 6 new U.S. hospital starts, CE Mark approval, and cash burn cut >30% to $7.6M; expects ex-U.S. shipments H1 2025, fiscal 2026 guidance in June; cash runway to spring 2026 contingent on revenue execution. - **2025 Q2:** Beyond Air reports 60% hospital client growth, targets positive gross margins by March 2025 quarter, extends cash runway to ~18 months via financing deals, awaits FDA cardiac surgery PMA supplement decision and CE Mark by year-end. - **2024 Q4:** Beyond Air reports FY24 revenue $1.2M, cuts FY25 guidance to >$10M from $12-16M, reduces headcount >20%, advances LungFit PH upgrades, cardiac surgery PMA supplement, oncology/autism pipelines. ## Theme arcs - **Revenue Growth** (improving): YoY revenue rose from $1.2M to $7.7M, with multiple hospital starts and international expansion - **Margin Profile** (improving): Gross loss narrowed and turned positive by 2026 Q1 after cost reductions ## Guidance path 2024 Q4:lowered → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:vague → 2026 Q3:vague → 2026 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/XAIR`